RELMADA THERAPEUTICS Business Summary

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotechnology company that operates on a value-creation model focused on the development of novel therapies for central nervous system (CNS) and oncology indications. The company currently generates no commercial product revenue, with its financial model relying on capital markets and potential future licensing or milestone payments from its pipeline of new chemical entities (NCEs). Its primary business segments are categorized into CNS disorders, headlined by the NMDA receptor antagonist REL-1017 (esmethadone) for Major Depressive Disorder, and Urology/Oncology, centered on the sustained-release formulation NDV-01 for non-muscle invasive bladder cancer. Direct competitors include Sage Therapeutics, Axsome Therapeutics, and Intra-Cellular Therapies in the depression market, and UroGen Pharma in the urologic oncology space. Relmada positions itself as a specialized developer of fast-acting, transformative treatments for high unmet needs, currently transitioning its lead oncology asset into registrational Phase 3 trials as of early 2026. The company was co-founded by current CEO Sergio Traversa, PharmD, MBA, and Najib Babul. Dr. Traversa possesses over 25 years of healthcare expertise, having previously co-founded Medeor Inc. and held senior investment roles at ING Barings and Mehta Partners. The core leadership team includes Chief Financial Officer Maged Shenouda, formerly of AzurRx BioPharma and Stifel Nicolaus, and Chief Operating Officer Paul Kelly, who assumed the role in January 2025. To drive its oncology strategy, the company appointed Dr. Raj S. Pruthi, a former leader at Johnson & Johnson and enGene Holdings, as Chief Medical Officer of Urology in mid-2025. The Board of Directors is led by Independent Chairman Charles J. Casamento and includes John Glasspool, CEO of Anthos Therapeutics. Relmada is supported by a diverse base of institutional investors, including Ikarian Capital, Vanguard Group, and State Street Corporation.